Share Price and Basic Stock Data
Last Updated: December 10, 2025, 9:34 pm
| PEG Ratio | -10.72 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Laurus Labs Ltd, a prominent player in the pharmaceutical sector, has demonstrated a commendable trajectory in revenue generation. For the fiscal year ending March 2023, the company reported sales of ₹5,773 Cr, marking a significant increase from ₹4,707 Cr in the previous year. However, the latest quarterly figures reveal a mixed performance; sales for March 2024 dipped to ₹4,812 Cr, followed by a recovery to ₹5,217 Cr in March 2025. This fluctuation hints at potential market volatility or operational challenges that the company may be facing. Notably, the company’s operational profit margin (OPM) stood at 26% for FY 2023, showcasing its ability to maintain profitability even with rising costs. The sales growth trajectory over the years seems robust, but the recent quarterly declines raise questions about sustainability and market dynamics. A closer examination of the product mix and market conditions may shed light on these trends.
Profitability and Efficiency Metrics
The profitability metrics of Laurus Labs reveal a company grappling with efficiency challenges. The operating profit margin, which stood at 26% in FY 2023, has seen a decline in subsequent quarters, dropping to 16% in September 2023 and 15% in December 2023. This decline in margins, coupled with a reported net profit of ₹510 Cr for the trailing twelve months, suggests that the company is facing pressure on its margins, likely due to rising input costs or pricing pressures in the market. Additionally, the return on equity (ROE) of 7.75% and return on capital employed (ROCE) of 9.47% appear subdued compared to industry standards, indicating that the company may not be utilizing its assets as effectively as its peers. The cash conversion cycle, currently at 262 days, also reflects operational inefficiencies that could hinder liquidity and operational agility.
Balance Sheet Strength and Financial Ratios
Laurus Labs maintains a relatively strong balance sheet, with total borrowings reported at ₹1,821 Cr against reserves of ₹4,810 Cr. This results in a comfortable debt-to-equity ratio of 0.60, indicating that the company is not overly reliant on debt for growth. However, the interest coverage ratio (ICR) of 5.55x suggests a manageable debt servicing capacity, although it is lower than previous years, where it peaked at over 14x in FY 2021. The current ratio of 1.22x indicates that Laurus Labs has sufficient short-term assets to cover its liabilities. However, the declining trend in both ROCE and net profit margins points to potential challenges in translating resources into returns. Investors should note that while the company’s financial structure appears stable, the efficiency in asset utilization and profit generation needs improvement to enhance shareholder value.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Laurus Labs reflects a diversified ownership structure, with promoters holding 27.60% and foreign institutional investors (FIIs) at 26.17%. This level of foreign investment indicates a reasonable degree of confidence in the company’s prospects, particularly as FIIs have been gradually increasing their stake over the past few quarters. Domestic institutional investors (DIIs) account for 11.72%, while the public holds 34.52%. The gradual decline in the number of shareholders from over 4 lakh to 2,83,678 may suggest some disenchantment among retail investors, possibly due to the company’s recent performance volatility. The stability in promoter holding, however, suggests a commitment to the company’s long-term vision, which could reassure investors about the management’s confidence in overcoming current challenges.
Outlook, Risks, and Final Insight
Looking ahead, Laurus Labs faces a mixed outlook characterized by both opportunities and risks. The pharmaceutical sector continues to grow, driven by increasing healthcare demands and innovation. However, the company’s recent profit margin contraction and declining quarterly sales raise concerns about its ability to sustain growth. Investors should be vigilant about operational efficiency, particularly in managing costs and optimizing the supply chain. Regulatory changes in the pharmaceutical landscape could also pose risks, impacting profitability. While the balance sheet appears sturdy, the declining ROE and cash conversion cycle need addressing to enhance shareholder value. Overall, investors must weigh Laurus Labs’ potential against the backdrop of its recent performance trends and broader market dynamics, keeping an eye on how effectively the company can navigate these challenges in a competitive environment.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Laurus Labs Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 142 Cr. | 113 | 239/84.3 | 31.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,177 Cr. | 383 | 479/192 | 86.5 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.4 Cr. | 43.6 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 45.3 Cr. | 30.9 | 31.0/17.0 | 108 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,300.00 Cr | 1,152.20 | 52.34 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,495 | 1,498 | 1,501 | 1,279 | 1,108 | 1,158 | 1,132 | 1,415 | 1,117 | 1,185 | 1,265 | 1,650 | 1,433 |
| Expenses | 1,077 | 1,072 | 1,116 | 1,027 | 980 | 978 | 962 | 1,143 | 956 | 1,003 | 1,059 | 1,255 | 1,105 |
| Operating Profit | 418 | 426 | 385 | 252 | 128 | 181 | 170 | 271 | 161 | 182 | 206 | 395 | 327 |
| OPM % | 28% | 28% | 26% | 20% | 12% | 16% | 15% | 19% | 14% | 15% | 16% | 24% | 23% |
| Other Income | 3 | 4 | 3 | 6 | 7 | 6 | 11 | 24 | 9 | 12 | 7 | 72 | 22 |
| Interest | 28 | 38 | 39 | 41 | 33 | 38 | 38 | 42 | 41 | 45 | 48 | 49 | 44 |
| Depreciation | 66 | 76 | 78 | 81 | 84 | 85 | 87 | 89 | 91 | 91 | 89 | 88 | 94 |
| Profit before tax | 328 | 317 | 270 | 137 | 17 | 63 | 57 | 164 | 39 | 58 | 77 | 330 | 211 |
| Tax % | 29% | 28% | 26% | 25% | 24% | 26% | 25% | 26% | 26% | 27% | 25% | 24% | 25% |
| Net Profit | 232 | 227 | 199 | 102 | 13 | 47 | 43 | 121 | 29 | 42 | 57 | 252 | 158 |
| EPS in Rs | 4.31 | 4.23 | 3.70 | 1.90 | 0.24 | 0.87 | 0.79 | 2.25 | 0.53 | 0.79 | 1.06 | 4.67 | 2.93 |
Last Updated: August 1, 2025, 6:00 pm
Below is a detailed analysis of the quarterly data for Laurus Labs Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1,433.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,650.00 Cr. (Mar 2025) to 1,433.00 Cr., marking a decrease of 217.00 Cr..
- For Expenses, as of Jun 2025, the value is 1,105.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1,255.00 Cr. (Mar 2025) to 1,105.00 Cr., marking a decrease of 150.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 327.00 Cr.. The value appears to be declining and may need further review. It has decreased from 395.00 Cr. (Mar 2025) to 327.00 Cr., marking a decrease of 68.00 Cr..
- For OPM %, as of Jun 2025, the value is 23.00%. The value appears to be declining and may need further review. It has decreased from 24.00% (Mar 2025) to 23.00%, marking a decrease of 1.00%.
- For Other Income, as of Jun 2025, the value is 22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 72.00 Cr. (Mar 2025) to 22.00 Cr., marking a decrease of 50.00 Cr..
- For Interest, as of Jun 2025, the value is 44.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 49.00 Cr. (Mar 2025) to 44.00 Cr., marking a decrease of 5.00 Cr..
- For Depreciation, as of Jun 2025, the value is 94.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 88.00 Cr. (Mar 2025) to 94.00 Cr., marking an increase of 6.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 211.00 Cr.. The value appears to be declining and may need further review. It has decreased from 330.00 Cr. (Mar 2025) to 211.00 Cr., marking a decrease of 119.00 Cr..
- For Tax %, as of Jun 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from 24.00% (Mar 2025) to 25.00%, marking an increase of 1.00%.
- For Net Profit, as of Jun 2025, the value is 158.00 Cr.. The value appears to be declining and may need further review. It has decreased from 252.00 Cr. (Mar 2025) to 158.00 Cr., marking a decrease of 94.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 2.93. The value appears to be declining and may need further review. It has decreased from 4.67 (Mar 2025) to 2.93, marking a decrease of 1.74.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:57 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,160 | 1,326 | 1,775 | 1,892 | 2,027 | 2,236 | 2,797 | 4,769 | 4,707 | 5,773 | 4,812 | 5,217 | 5,533 |
| Expenses | 951 | 1,121 | 1,402 | 1,478 | 1,618 | 1,884 | 2,226 | 3,258 | 3,421 | 4,292 | 4,062 | 4,273 | 4,422 |
| Operating Profit | 209 | 205 | 372 | 414 | 409 | 352 | 571 | 1,511 | 1,286 | 1,482 | 751 | 944 | 1,110 |
| OPM % | 18% | 15% | 21% | 22% | 20% | 16% | 20% | 32% | 27% | 26% | 16% | 18% | 20% |
| Other Income | 9 | 34 | 4 | 32 | 28 | 15 | 5 | 26 | 20 | 16 | 47 | 100 | 113 |
| Interest | 64 | 106 | 111 | 97 | 75 | 86 | 88 | 66 | 96 | 146 | 151 | 182 | 185 |
| Depreciation | 33 | 61 | 86 | 104 | 121 | 161 | 184 | 197 | 235 | 301 | 345 | 359 | 361 |
| Profit before tax | 121 | 72 | 180 | 245 | 241 | 121 | 304 | 1,275 | 975 | 1,051 | 301 | 504 | 676 |
| Tax % | 20% | -2% | 19% | 18% | 28% | 22% | 12% | 25% | 23% | 28% | 26% | 24% | |
| Net Profit | 97 | 74 | 145 | 200 | 173 | 95 | 267 | 956 | 750 | 760 | 224 | 380 | 510 |
| EPS in Rs | 12.64 | 9.47 | 18.36 | 3.78 | 3.27 | 1.78 | 5.00 | 17.82 | 13.96 | 14.12 | 4.15 | 7.05 | 9.45 |
| Dividend Payout % | 0% | 0% | 2% | 8% | 9% | 17% | 10% | 11% | 14% | 14% | 19% | 17% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -23.71% | 95.95% | 37.93% | -13.50% | -45.09% | 181.05% | 258.05% | -21.55% | 1.33% | -70.53% | 69.64% |
| Change in YoY Net Profit Growth (%) | 0.00% | 119.66% | -58.01% | -51.43% | -31.59% | 226.14% | 77.00% | -279.60% | 22.88% | -71.86% | 140.17% |
Laurus Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 13% |
| 3 Years: | 3% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 5% |
| 3 Years: | -23% |
| TTM: | 113% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 30% |
| 3 Years: | 16% |
| 1 Year: | 79% |
| Return on Equity | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 17% |
| 3 Years: | 11% |
| Last Year: | 8% |
Last Updated: September 5, 2025, 9:40 am
Balance Sheet
Last Updated: December 4, 2025, 1:34 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15 | 16 | 16 | 106 | 106 | 106 | 107 | 107 | 107 | 108 | 108 | 108 | 108 |
| Reserves | 281 | 645 | 790 | 1,250 | 1,407 | 1,484 | 1,709 | 2,605 | 3,281 | 3,949 | 4,099 | 4,456 | 4,810 |
| Borrowings | 605 | 888 | 1,081 | 808 | 947 | 1,009 | 1,051 | 1,411 | 1,653 | 1,714 | 2,110 | 2,380 | 1,821 |
| Other Liabilities | 372 | 344 | 342 | 509 | 547 | 718 | 872 | 1,502 | 1,567 | 1,187 | 1,351 | 1,643 | 1,953 |
| Total Liabilities | 1,273 | 1,893 | 2,229 | 2,673 | 3,008 | 3,318 | 3,739 | 5,625 | 6,609 | 6,958 | 7,667 | 8,587 | 8,692 |
| Fixed Assets | 499 | 801 | 1,014 | 1,193 | 1,448 | 1,599 | 1,694 | 1,818 | 2,186 | 2,884 | 3,036 | 2,888 | 2,946 |
| CWIP | 116 | 107 | 70 | 143 | 163 | 107 | 67 | 324 | 755 | 357 | 156 | 336 | 438 |
| Investments | 0 | 19 | 26 | 51 | 52 | 58 | 58 | 319 | 362 | 384 | 635 | 740 | 807 |
| Other Assets | 658 | 966 | 1,119 | 1,286 | 1,345 | 1,554 | 1,920 | 3,164 | 3,306 | 3,333 | 3,841 | 4,623 | 4,501 |
| Total Assets | 1,273 | 1,893 | 2,229 | 2,673 | 3,008 | 3,318 | 3,739 | 5,625 | 6,609 | 6,958 | 7,667 | 8,587 | 8,692 |
Below is a detailed analysis of the balance sheet data for Laurus Labs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 108.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 108.00 Cr..
- For Reserves, as of Sep 2025, the value is 4,810.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,456.00 Cr. (Mar 2025) to 4,810.00 Cr., marking an increase of 354.00 Cr..
- For Borrowings, as of Sep 2025, the value is 1,821.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 2,380.00 Cr. (Mar 2025) to 1,821.00 Cr., marking a decrease of 559.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,953.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,643.00 Cr. (Mar 2025) to 1,953.00 Cr., marking an increase of 310.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 8,692.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 8,587.00 Cr. (Mar 2025) to 8,692.00 Cr., marking an increase of 105.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 2,946.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,888.00 Cr. (Mar 2025) to 2,946.00 Cr., marking an increase of 58.00 Cr..
- For CWIP, as of Sep 2025, the value is 438.00 Cr.. The value appears strong and on an upward trend. It has increased from 336.00 Cr. (Mar 2025) to 438.00 Cr., marking an increase of 102.00 Cr..
- For Investments, as of Sep 2025, the value is 807.00 Cr.. The value appears strong and on an upward trend. It has increased from 740.00 Cr. (Mar 2025) to 807.00 Cr., marking an increase of 67.00 Cr..
- For Other Assets, as of Sep 2025, the value is 4,501.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4,623.00 Cr. (Mar 2025) to 4,501.00 Cr., marking a decrease of 122.00 Cr..
- For Total Assets, as of Sep 2025, the value is 8,692.00 Cr.. The value appears strong and on an upward trend. It has increased from 8,587.00 Cr. (Mar 2025) to 8,692.00 Cr., marking an increase of 105.00 Cr..
Notably, the Reserves (4,810.00 Cr.) exceed the Borrowings (1,821.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -396.00 | -683.00 | 371.00 | -394.00 | -538.00 | 351.00 | 570.00 | 0.00 | 0.00 | 0.00 | 749.00 | 942.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 61 | 78 | 91 | 108 | 100 | 112 | 102 | 98 | 98 | 94 | 124 | 142 |
| Inventory Days | 165 | 210 | 177 | 184 | 199 | 201 | 233 | 257 | 279 | 211 | 258 | 258 |
| Days Payable | 114 | 101 | 91 | 110 | 106 | 144 | 157 | 194 | 140 | 90 | 151 | 138 |
| Cash Conversion Cycle | 112 | 187 | 177 | 183 | 193 | 169 | 177 | 161 | 237 | 216 | 231 | 262 |
| Working Capital Days | -50 | -0 | 20 | 7 | -7 | 9 | 19 | 50 | 57 | 67 | 56 | 56 |
| ROCE % | 25% | 15% | 17% | 17% | 14% | 8% | 14% | 38% | 23% | 22% | 8% | 9% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Mirae Asset Large & Midcap Fund | 6,671,181 | 1.48 | 636.2 | N/A | N/A | N/A |
| SBI Large & Midcap Fund | 5,392,600 | 1.45 | 514.27 | N/A | N/A | N/A |
| Mirae Asset ELSS Tax Saver Fund | 5,023,466 | 1.77 | 479.06 | N/A | N/A | N/A |
| Mirae Asset Midcap Fund | 3,071,035 | 1.62 | 292.87 | 4,110,034 | 2025-12-08 03:11:13 | -25.28% |
| DSP Healthcare Fund | 2,217,884 | 6.73 | 211.51 | N/A | N/A | N/A |
| Axis Small Cap Fund | 2,117,487 | 0.75 | 201.93 | 1,589,977 | 2025-12-08 03:11:13 | 33.18% |
| Mahindra Manulife Multi Cap Fund | 1,477,233 | 2.33 | 140.88 | N/A | N/A | N/A |
| SBI Healthcare Opportunities Fund | 1,400,000 | 3.27 | 133.51 | N/A | N/A | N/A |
| Tata Arbitrage Fund | 1,182,350 | 0.56 | 112.75 | N/A | N/A | N/A |
| DSP Large & Mid Cap Fund | 1,017,010 | 0.59 | 96.99 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 6.65 | 2.98 | 14.69 | 15.42 | 18.36 |
| Diluted EPS (Rs.) | 6.64 | 2.97 | 14.64 | 15.42 | 18.28 |
| Cash EPS (Rs.) | 14.56 | 10.26 | 20.81 | 20.17 | 22.16 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 82.99 | 76.28 | 75.16 | 62.51 | 48.47 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 82.99 | 76.28 | 75.16 | 62.51 | 48.47 |
| Revenue From Operations / Share (Rs.) | 103.05 | 93.53 | 112.14 | 91.85 | 89.70 |
| PBDIT / Share (Rs.) | 20.69 | 14.91 | 29.67 | 26.72 | 29.34 |
| PBIT / Share (Rs.) | 12.71 | 7.78 | 23.65 | 22.04 | 25.52 |
| PBT / Share (Rs.) | 8.99 | 4.39 | 20.59 | 20.17 | 24.25 |
| Net Profit / Share (Rs.) | 6.58 | 3.12 | 14.79 | 15.49 | 18.33 |
| NP After MI And SOA / Share (Rs.) | 6.65 | 2.98 | 14.67 | 15.40 | 18.33 |
| PBDIT Margin (%) | 20.07 | 15.94 | 26.45 | 29.09 | 32.70 |
| PBIT Margin (%) | 12.33 | 8.31 | 21.09 | 23.99 | 28.44 |
| PBT Margin (%) | 8.71 | 4.68 | 18.35 | 21.95 | 27.03 |
| Net Profit Margin (%) | 6.38 | 3.33 | 13.18 | 16.86 | 20.43 |
| NP After MI And SOA Margin (%) | 6.45 | 3.18 | 13.08 | 16.76 | 20.43 |
| Return on Networth / Equity (%) | 8.01 | 3.90 | 19.56 | 24.69 | 37.86 |
| Return on Capital Employeed (%) | 11.82 | 7.94 | 24.37 | 27.63 | 41.57 |
| Return On Assets (%) | 3.83 | 1.91 | 10.31 | 11.87 | 17.10 |
| Long Term Debt / Equity (X) | 0.14 | 0.19 | 0.18 | 0.17 | 0.16 |
| Total Debt / Equity (X) | 0.60 | 0.60 | 0.48 | 0.51 | 0.50 |
| Asset Turnover Ratio (%) | 0.62 | 0.62 | 0.82 | 0.76 | 1.02 |
| Current Ratio (X) | 1.22 | 1.23 | 1.42 | 1.25 | 1.25 |
| Quick Ratio (X) | 0.67 | 0.63 | 0.73 | 0.59 | 0.61 |
| Inventory Turnover Ratio (X) | 1.28 | 1.37 | 1.51 | 1.40 | 1.95 |
| Dividend Payout Ratio (NP) (%) | 12.03 | 53.67 | 13.60 | 10.37 | 7.62 |
| Dividend Payout Ratio (CP) (%) | 5.47 | 15.80 | 9.64 | 7.95 | 6.31 |
| Earning Retention Ratio (%) | 87.97 | 46.33 | 86.40 | 89.63 | 92.38 |
| Cash Earning Retention Ratio (%) | 94.53 | 84.20 | 90.36 | 92.05 | 93.69 |
| Interest Coverage Ratio (X) | 5.55 | 4.39 | 9.68 | 14.26 | 23.10 |
| Interest Coverage Ratio (Post Tax) (X) | 2.76 | 1.92 | 5.82 | 9.27 | 15.43 |
| Enterprise Value (Cr.) | 35759.58 | 23483.39 | 17717.09 | 33370.29 | 20697.57 |
| EV / Net Operating Revenue (X) | 6.44 | 4.66 | 2.93 | 6.76 | 4.30 |
| EV / EBITDA (X) | 32.07 | 29.21 | 11.09 | 23.24 | 13.15 |
| MarketCap / Net Operating Revenue (X) | 5.96 | 4.19 | 2.61 | 6.42 | 4.04 |
| Retention Ratios (%) | 87.96 | 46.32 | 86.39 | 89.62 | 92.37 |
| Price / BV (X) | 7.40 | 5.14 | 3.91 | 9.46 | 7.48 |
| Price / Net Operating Revenue (X) | 5.96 | 4.19 | 2.61 | 6.42 | 4.04 |
| EarningsYield | 0.01 | 0.01 | 0.05 | 0.02 | 0.05 |
After reviewing the key financial ratios for Laurus Labs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 6.65. This value is within the healthy range. It has increased from 2.98 (Mar 24) to 6.65, marking an increase of 3.67.
- For Diluted EPS (Rs.), as of Mar 25, the value is 6.64. This value is within the healthy range. It has increased from 2.97 (Mar 24) to 6.64, marking an increase of 3.67.
- For Cash EPS (Rs.), as of Mar 25, the value is 14.56. This value is within the healthy range. It has increased from 10.26 (Mar 24) to 14.56, marking an increase of 4.30.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 82.99. It has increased from 76.28 (Mar 24) to 82.99, marking an increase of 6.71.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 82.99. It has increased from 76.28 (Mar 24) to 82.99, marking an increase of 6.71.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 103.05. It has increased from 93.53 (Mar 24) to 103.05, marking an increase of 9.52.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 20.69. This value is within the healthy range. It has increased from 14.91 (Mar 24) to 20.69, marking an increase of 5.78.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.71. This value is within the healthy range. It has increased from 7.78 (Mar 24) to 12.71, marking an increase of 4.93.
- For PBT / Share (Rs.), as of Mar 25, the value is 8.99. This value is within the healthy range. It has increased from 4.39 (Mar 24) to 8.99, marking an increase of 4.60.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 6.58. This value is within the healthy range. It has increased from 3.12 (Mar 24) to 6.58, marking an increase of 3.46.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 6.65. This value is within the healthy range. It has increased from 2.98 (Mar 24) to 6.65, marking an increase of 3.67.
- For PBDIT Margin (%), as of Mar 25, the value is 20.07. This value is within the healthy range. It has increased from 15.94 (Mar 24) to 20.07, marking an increase of 4.13.
- For PBIT Margin (%), as of Mar 25, the value is 12.33. This value is within the healthy range. It has increased from 8.31 (Mar 24) to 12.33, marking an increase of 4.02.
- For PBT Margin (%), as of Mar 25, the value is 8.71. This value is below the healthy minimum of 10. It has increased from 4.68 (Mar 24) to 8.71, marking an increase of 4.03.
- For Net Profit Margin (%), as of Mar 25, the value is 6.38. This value is within the healthy range. It has increased from 3.33 (Mar 24) to 6.38, marking an increase of 3.05.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.45. This value is below the healthy minimum of 8. It has increased from 3.18 (Mar 24) to 6.45, marking an increase of 3.27.
- For Return on Networth / Equity (%), as of Mar 25, the value is 8.01. This value is below the healthy minimum of 15. It has increased from 3.90 (Mar 24) to 8.01, marking an increase of 4.11.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.82. This value is within the healthy range. It has increased from 7.94 (Mar 24) to 11.82, marking an increase of 3.88.
- For Return On Assets (%), as of Mar 25, the value is 3.83. This value is below the healthy minimum of 5. It has increased from 1.91 (Mar 24) to 3.83, marking an increase of 1.92.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.14. This value is below the healthy minimum of 0.2. It has decreased from 0.19 (Mar 24) to 0.14, marking a decrease of 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.60. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.60.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.62. There is no change compared to the previous period (Mar 24) which recorded 0.62.
- For Current Ratio (X), as of Mar 25, the value is 1.22. This value is below the healthy minimum of 1.5. It has decreased from 1.23 (Mar 24) to 1.22, marking a decrease of 0.01.
- For Quick Ratio (X), as of Mar 25, the value is 0.67. This value is below the healthy minimum of 1. It has increased from 0.63 (Mar 24) to 0.67, marking an increase of 0.04.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.28. This value is below the healthy minimum of 4. It has decreased from 1.37 (Mar 24) to 1.28, marking a decrease of 0.09.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 12.03. This value is below the healthy minimum of 20. It has decreased from 53.67 (Mar 24) to 12.03, marking a decrease of 41.64.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 5.47. This value is below the healthy minimum of 20. It has decreased from 15.80 (Mar 24) to 5.47, marking a decrease of 10.33.
- For Earning Retention Ratio (%), as of Mar 25, the value is 87.97. This value exceeds the healthy maximum of 70. It has increased from 46.33 (Mar 24) to 87.97, marking an increase of 41.64.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 94.53. This value exceeds the healthy maximum of 70. It has increased from 84.20 (Mar 24) to 94.53, marking an increase of 10.33.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.55. This value is within the healthy range. It has increased from 4.39 (Mar 24) to 5.55, marking an increase of 1.16.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.76. This value is below the healthy minimum of 3. It has increased from 1.92 (Mar 24) to 2.76, marking an increase of 0.84.
- For Enterprise Value (Cr.), as of Mar 25, the value is 35,759.58. It has increased from 23,483.39 (Mar 24) to 35,759.58, marking an increase of 12,276.19.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 6.44. This value exceeds the healthy maximum of 3. It has increased from 4.66 (Mar 24) to 6.44, marking an increase of 1.78.
- For EV / EBITDA (X), as of Mar 25, the value is 32.07. This value exceeds the healthy maximum of 15. It has increased from 29.21 (Mar 24) to 32.07, marking an increase of 2.86.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.96. This value exceeds the healthy maximum of 3. It has increased from 4.19 (Mar 24) to 5.96, marking an increase of 1.77.
- For Retention Ratios (%), as of Mar 25, the value is 87.96. This value exceeds the healthy maximum of 70. It has increased from 46.32 (Mar 24) to 87.96, marking an increase of 41.64.
- For Price / BV (X), as of Mar 25, the value is 7.40. This value exceeds the healthy maximum of 3. It has increased from 5.14 (Mar 24) to 7.40, marking an increase of 2.26.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.96. This value exceeds the healthy maximum of 3. It has increased from 4.19 (Mar 24) to 5.96, marking an increase of 1.77.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Laurus Labs Ltd:
- Net Profit Margin: 6.38%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.82% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 8.01% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.76
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.67
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 80.5 (Industry average Stock P/E: 52.34)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.6
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 6.38%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Laurus Enclave, Plot Office 01, Edulapakabonangi Village, Vishakapatnam Andhra Pradesh 531021 | secretarial@lauruslabs.com https://www.lauruslabs.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Ravindranath Kancherla | Non Exe.Chairman&Ind.Director |
| Mr. V V Ravi Kumar | Executive Director & CFO |
| Dr. Satyanarayana Chava | Executive Director & CEO |
| Ms. Soumya Chava | Executive Director |
| Dr. C V Lakshmana Rao | Executive Director |
| Mr. Krishna Chaitanya Chava | Executive Director |
| Mrs. Aruna Rajendra Bhinge | Independent Director |
| Mr. Karnam Sekar | Independent Director |
| Dr. Rajesh Koshy Chandy | Independent Director |
| Mr. Ramesh Subrahmanian | Independent Director |
FAQ
What is the intrinsic value of Laurus Labs Ltd?
Laurus Labs Ltd's intrinsic value (as of 10 December 2025) is 455.23 which is 55.28% lower the current market price of 1,018.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 54,976 Cr. market cap, FY2025-2026 high/low of 1,040/501, reserves of ₹4,810 Cr, and liabilities of 8,692 Cr.
What is the Market Cap of Laurus Labs Ltd?
The Market Cap of Laurus Labs Ltd is 54,976 Cr..
What is the current Stock Price of Laurus Labs Ltd as on 10 December 2025?
The current stock price of Laurus Labs Ltd as on 10 December 2025 is 1,018.
What is the High / Low of Laurus Labs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Laurus Labs Ltd stocks is 1,040/501.
What is the Stock P/E of Laurus Labs Ltd?
The Stock P/E of Laurus Labs Ltd is 80.5.
What is the Book Value of Laurus Labs Ltd?
The Book Value of Laurus Labs Ltd is 91.1.
What is the Dividend Yield of Laurus Labs Ltd?
The Dividend Yield of Laurus Labs Ltd is 0.12 %.
What is the ROCE of Laurus Labs Ltd?
The ROCE of Laurus Labs Ltd is 9.47 %.
What is the ROE of Laurus Labs Ltd?
The ROE of Laurus Labs Ltd is 7.75 %.
What is the Face Value of Laurus Labs Ltd?
The Face Value of Laurus Labs Ltd is 2.00.